Mark H. Rozenbaum

2.5k total citations · 1 hit paper
73 papers, 1.7k citations indexed

About

Mark H. Rozenbaum is a scholar working on Epidemiology, Molecular Biology and Nephrology. According to data from OpenAlex, Mark H. Rozenbaum has authored 73 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Epidemiology, 15 papers in Molecular Biology and 11 papers in Nephrology. Recurrent topics in Mark H. Rozenbaum's work include Pneumonia and Respiratory Infections (29 papers), Respiratory viral infections research (22 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers). Mark H. Rozenbaum is often cited by papers focused on Pneumonia and Respiratory Infections (29 papers), Respiratory viral infections research (22 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers). Mark H. Rozenbaum collaborates with scholars based in Netherlands, United States and United Kingdom. Mark H. Rozenbaum's co-authors include Maarten J. Postma, Eelko Hak, Tjip S. van der Werf, Albert Jan van Hoek, Marie‐Josée J. Mangen, Stefan Vegter, Elizabeth Begier, Susanne M. Huijts, Cornelis Boersma and Elisabeth A. M. Sanders and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark H. Rozenbaum

67 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis

2023 99 citations Daniel Curcio, Bradford D. Gessner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark H. Rozenbaum Netherlands	26	1.0k	316	258	201	187	73	1.7k
Chad J. Achenbach United States	28	707 0.7×	964 3.1×	202 0.8×	126 0.6×	47 0.3×	124	2.5k
Daniel Grima Canada	18	664 0.6×	86 0.3×	157 0.6×	188 0.9×	52 0.3×	67	1.7k
Catherine Cohet Belgium	20	563 0.5×	207 0.7×	155 0.6×	59 0.3×	46 0.2×	45	1.3k
Lisa J. McGarry United States	19	681 0.7×	82 0.3×	47 0.2×	66 0.3×	170 0.9×	70	1.5k
Patrick Zuber Switzerland	24	733 0.7×	651 2.1×	84 0.3×	35 0.2×	139 0.7×	52	1.6k
Maria Elena Tosti Italy	33	1.7k 1.7×	652 2.1×	178 0.7×	45 0.2×	47 0.3×	125	2.9k
Jeannette Lee United States	16	245 0.2×	525 1.7×	325 1.3×	45 0.2×	58 0.3×	37	1.7k
Carlo Lucioni Italy	16	361 0.3×	68 0.2×	58 0.2×	243 1.2×	39 0.2×	76	1.1k
Marian Ewell United States	21	801 0.8×	141 0.4×	127 0.5×	18 0.1×	59 0.3×	33	2.4k
Carla Carrilho Mozambique	24	524 0.5×	149 0.5×	126 0.5×	42 0.2×	23 0.1×	98	1.7k

Countries citing papers authored by Mark H. Rozenbaum

Since Specialization

Citations

This map shows the geographic impact of Mark H. Rozenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H. Rozenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H. Rozenbaum more than expected).

Fields of papers citing papers by Mark H. Rozenbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H. Rozenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H. Rozenbaum. The network helps show where Mark H. Rozenbaum may publish in the future.

Co-authorship network of co-authors of Mark H. Rozenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Mark H. Rozenbaum. A scholar is included among the top collaborators of Mark H. Rozenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark H. Rozenbaum. Mark H. Rozenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rozenbaum, Mark H., Blair Capitano, Ruth Chapman, et al.. (2025). A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to Vaccinate. Vaccines. 13(8). 805–805.

Weycker, Derek, Rotem Lapidot, Mark H. Rozenbaum, et al.. (2025). Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children. Journal of Medical Economics. 28(1). 517–523.

Cané, Alejandro, et al.. (2024). The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US. Vaccines. 12(11). 1279–1279. 1 indexed citations

Rozenbaum, Mark H., Liping Huang, Alejandro Cané, et al.. (2024). Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. Journal of Medical Economics. 27(1). 644–652. 6 indexed citations

Rozenbaum, Mark H., Liping Huang, Johnna Perdrizet, et al.. (2024). Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine. 42(3). 573–582. 10 indexed citations

Weycker, Derek, Kimberly M. Shea, Reiko Sato, et al.. (2024). Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious Diseases and Therapy. 13(1). 207–220. 8 indexed citations

Rozenbaum, Mark H., et al.. (2023). Endoscopic implantation of autologous myoblasts for stress urinary incontinence and evaluation of its efficacy in sphincterotomized rabbits. Actas Urológicas Españolas (English Edition). 47(9). 588–597.

Rozenbaum, Mark H., Elizabeth Begier, Samantha K. Kurosky, et al.. (2023). Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infectious Diseases and Therapy. 12(6). 1487–1504. 48 indexed citations

Johansson, Katarina, Mark H. Rozenbaum, Anne Mette Strand, et al.. (2022). Healthcare Resource Use of Patients with Transthyretin Amyloid Cardiomyopathy. ESC Heart Failure. 9(3). 1636–1642. 6 indexed citations

10.

Li, Hui‐Hua, Mark H. Rozenbaum, Michelle Casey, & Marla B. Sultan. (2022). Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death. Cardiology. 147(4). 398–405. 10 indexed citations

11.

Postma, Maarten J., et al.. (2022). The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. Value in Health. 26(1). 91–98. 5 indexed citations

12.

Rozenbaum, Mark H., Rahul Bhambri, Michelle Stewart, et al.. (2021). Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiology and Therapy. 10(1). 141–159. 67 indexed citations

13.

Stevanović, Jelena, et al.. (2014). Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands. PLoS ONE. 9(8). e103974–e103974. 29 indexed citations

14.

Tu, Hong, et al.. (2013). An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”. BMC Infectious Diseases. 13(1). 54–54. 26 indexed citations

15.

Vu, Dinh Hoa, et al.. (2012). A review of the literature on the economics of vaccination against TB. Expert Review of Vaccines. 11(3). 303–317. 14 indexed citations

16.

Rozenbaum, Mark H., Cornelis Boersma, Maarten J. Postma, & Eelko Hak. (2011). Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Review of Vaccines. 10(2). 187–199. 29 indexed citations

17.

Rozenbaum, Mark H., et al.. (2010). Possible role of cost-effectiveness of HPV vaccination within the decision context on inclusion of HPV in the country-specific national immunization programs. Data Archiving and Networked Services (DANS). 1 indexed citations

18.

Rozenbaum, Mark H., Albert Jan van Hoek, Eelko Hak, & Maarten J. Postma. (2010). Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®). Vaccine. 28(12). 2367–2369. 25 indexed citations

19.

Rozenbaum, Mark H., Paul B. van den Berg, Eelko Hak, et al.. (2008). Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination. Vaccine. 27(7). 1119–1126. 8 indexed citations

20.

Eder, Lihi, Devy Zisman, Mark H. Rozenbaum, & Itzhak Rosner. (2005). Clinical features and aetiology of septic arthritis in northern Israel. Lara D. Veeken. 44(12). 1559–1563. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact